Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Phase 3

Completed

Conditions: Factor XIII Deficiency

Interventions: Biological: FXIII Concentrate (Human)

First Posted Date: 2009-04-22

Last Posted Date: 2012-07-16

Lead Sponsor: CSL Behring

Target Recruit Count: 41

Registration Number: NCT00885742

Locations: 🇪🇸
Study Site, Santa Cruz de Tenerife, Spain
🇺🇸
Study, Miami, Florida, United States

A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

Phase 2

Completed

Conditions: Factor XIII Deficiency

Interventions: Biological: FXIII Concentrate (Human)

First Posted Date: 2009-04-17

Last Posted Date: 2012-01-16

Lead Sponsor: CSL Behring

Target Recruit Count: 15

Registration Number: NCT00883090

Locations: 🇪🇸
Study Site, Santa Cruz de Tenerife, Spain

Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A

Phase 2

Completed

Conditions: Hemophilia A

Interventions: Biological: Biostate® [SP]
Biological: Biostate® [RP]

First Posted Date: 2009-04-10

Last Posted Date: 2011-02-11

Lead Sponsor: CSL Behring

Target Recruit Count: 81

Registration Number: NCT00879541

Locations: 🇷🇺
Study Site, Moscow, Russian Federation

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

Phase 2

Completed

Conditions: NSCLC
Fatigue
Cachexia

Interventions: Biological: ALD518
Biological: Infusion of 0.9% Saline without ALD518

First Posted Date: 2009-03-23

Last Posted Date: 2020-07-09

Lead Sponsor: CSL Behring

Target Recruit Count: 124

Registration Number: NCT00866970

Locations: 🇦🇺
Rivercity Hospital Research Centre, Auchenflower, Queensland, Australia
🇦🇺
Australian Clinical Research Organisation, Kippa Ring, Queensland, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 40 locations

Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Biological: Infusion without ALD518'
Biological: ALD518

First Posted Date: 2009-03-23

Last Posted Date: 2020-07-09

Lead Sponsor: CSL Behring

Target Recruit Count: 127

Registration Number: NCT00867516

Locations: 🇨🇦
K-W Musculoskeletal Research, Inc., Kitchener, Ontario, Canada
🇨🇦
Rheumatology Research Associates, Ottawa, Ontario, Canada
🇬🇪
V. Tsitlanadze Scientific Practical Centre of Rheumatology, Tbilisi, Georgia

and more 23 locations

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure

Phase 3

Completed

Conditions: Reversal of Coagulopathy

Interventions: Biological: Beriplex® P/N (Kcentra)
Biological: Fresh frozen plasma

First Posted Date: 2008-12-05

Last Posted Date: 2015-04-06

Lead Sponsor: CSL Behring

Target Recruit Count: 176

Registration Number: NCT00803101

Locations: 🇷🇺
Study Site, Saint Petersburg, Russian Federation
🇺🇸
Study site, Bryan, Texas, United States
🇷🇺
Study Site 1, Moscow, Russian Federation

and more 2 locations

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Phase 3

Completed

Conditions: Primary Immunodeficiency (PID)

Interventions: Biological: IgPro20

First Posted Date: 2008-09-12

Last Posted Date: 2014-04-02

Lead Sponsor: CSL Behring

Target Recruit Count: 40

Registration Number: NCT00751621

Locations: 🇬🇧
Study Site, London, United Kingdom

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

Phase 3

Completed

Conditions: Primary Immune Deficiency

Interventions: Biological: IgPro20

First Posted Date: 2008-07-22

Last Posted Date: 2014-04-02

Lead Sponsor: CSL Behring

Target Recruit Count: 21

Registration Number: NCT00719680

Locations: 🇺🇸
Contact CSL Behring for facility details, Dallas, Texas, United States

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Phase 3

Completed

Conditions: Blood Coagulation Disorders
Acute Major Bleeding

Interventions: Biological: Fresh frozen plasma
Biological: Beriplex® P/N (Kcentra)

First Posted Date: 2008-07-02

Last Posted Date: 2014-02-03

Lead Sponsor: CSL Behring

Target Recruit Count: 216

Registration Number: NCT00708435

Locations: 🇺🇦
Study Site, Vinnytsa, Ukraine
🇷🇺
Study Site 2, St. Petersburg, Russian Federation
🇷🇺
Study Site 1, St. Petersburg, Russian Federation

and more 2 locations

A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)

Phase 2

Completed

Conditions: Multifocal Motor Neuropathy (MMN)

Interventions: Biological: Vivaglobin

First Posted Date: 2008-06-19

Last Posted Date: 2013-08-01

Lead Sponsor: CSL Behring

Target Recruit Count: 8

Registration Number: NCT00701662

Locations: 🇮🇹
San Raffaele Hospital, Milan, Italy
🇨🇭
Inselspital, Bern, Switzerland
🇬🇧
Dept. Clinical Immunology, Oxford Radcliffe Hospitals, Oxford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy